These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29371538)

  • 1. An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis.
    Tupaki-Sreepurna A; Jishnu BT; Thanneru V; Sharma S; Gopi A; Sundaram M; Jyoti Kindo A
    J Fungi (Basel); 2017 May; 3(2):. PubMed ID: 29371538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
    Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efinaconazole: a new topical treatment for onychomycosis.
    Gupta AK; Simpson FC
    Skin Therapy Lett; 2014; 19(1):1-4. PubMed ID: 24570290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efinaconazole (Jublia) for the treatment of onychomycosis.
    Gupta AK; Simpson FC
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):743-52. PubMed ID: 24850511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
    Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
    Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.
    Del Rosso JQ
    J Clin Aesthet Dermatol; 2014 Jul; 7(7):10-8. PubMed ID: 25053979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.
    Vlahovic TC; Gupta AK
    Expert Rev Anti Infect Ther; 2022 Jan; 20(1):3-15. PubMed ID: 34106031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
    Pollak RA
    J Am Podiatr Med Assoc; 2014 Nov; 104(6):568-73. PubMed ID: 25514267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.
    Matsuda Y; Sugiura K; Hashimoto T; Ueda A; Konno Y; Tatsumi Y
    PLoS One; 2016; 11(7):e0159661. PubMed ID: 27441843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How effective is efinaconazole in the management of onychomycosis?
    Gupta AK; Cernea M
    Expert Opin Pharmacother; 2016; 17(4):611-8. PubMed ID: 26809447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK; Konnikov N; Lynde CW
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis.
    Pakshir K; Kamali M; Nouraei H; Zomorodian K; Motamedi M; Mahmoodi M
    Sci Rep; 2021 Oct; 11(1):20736. PubMed ID: 34671053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success.
    Pollak RA; Siu WJJ; Tatsumi Y; Pillai R
    J Fungi (Basel); 2015 Jul; 1(2):107-114. PubMed ID: 29376902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.
    Iwata A; Watanabe Y; Kumagai N; Katafuchi-Nagashima M; Sugiura K; Pillai R; Tatsumi Y
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4920-2. PubMed ID: 24867968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ; Scott LJ; Goa KL
    Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for predicting the efficacy of topical drugs on onychomycosis: A comparison of efinaconazole and luliconazole.
    Masumoto A; Takagi M; Sugiura K; Matsuda Y; Nakamura S; Tatsumi Y
    J Mycol Med; 2022 Aug; 32(3):101259. PubMed ID: 35255449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversity of phenotypically non-dermatophyte, non-Aspergillus filamentous fungi causing nail infections: importance of accurate identification and antifungal susceptibility testing.
    Tsang CC; Tang JYM; Chan KF; Lee CY; Chan JFW; Ngan AHY; Cheung M; Lau ECL; Li X; Ng RHY; Lai CKC; Fung KSC; Lau SKP; Woo PCY
    Emerg Microbes Infect; 2019; 8(1):531-541. PubMed ID: 30938262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
    Kawai M
    Med Mycol J; 2019; 60(3):71-74. PubMed ID: 31474693
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.